MB-07811 | CAS#852948-13-1 | TRβ agonist

MedKoo Cat#: 466215 | Name: MB07811

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MB07811, also known as VK2809, is an orally bioavailable, liver-targeted prodrug of MB07344, which is a thyroid hormone receptor-beta agonist (TRβ) agonist, efficiently converted to MB07344 by liver microsomes in vivo. MB07811 lowers Plasma Cholesterol in Cynomolgus Monkeys as Effectively as Atorvastatin. MB07811 demonstrates promising cholesterol lowering activity without inducing tachycardia or other side effects in cynomolgus monkeys.

Chemical Structure

MB07811

CAS#852948-13-1 (2R4S)

Theoretical Analysis

MedKoo Cat#: 466215

Name: MB07811

CAS#: 852948-13-1 (2R4S)

Chemical Formula: C28H32ClO5P

Exact Mass: 514.1676

Molecular Weight: 514.98

Elemental Analysis: C, 65.30; H, 6.26; Cl, 6.88; O, 15.53; P, 6.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

916055-16-8 (racemate) 852948-13-1 (2R4S) 915233-90-8 (2S4R)

Synonym

MB-07811; MB07811; MB 07811; VK2809; VK-2809; VK 2809;

IUPAC/Chemical Name

Phenol, 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-(1-methylethyl)-

InChi Key

LGGPZDRLTDGYSQ-JADSYQMUSA-N

InChi Code

InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1

SMILES Code

OC1=CC=C(CC2=C(C)C=C(OC[P@]3(OCC[C@@H](C4=CC=CC(Cl)=C4)O3)=O)C=C2C)C=C1C(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 514.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Luong XG, Stevens SK, Jekle A, Lin TI, Gupta K, Misner D, Chanda S, Mukherjee S, Williams C, Stoycheva A, Blatt LM, Beigelman LN, Symons JA, Raboisson P, McGowan D, Vandyck K, Deval J. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non- alcoholic steatohepatitis (NASH). PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. PMID: 33306682; PMCID: PMC7732128. 2: Zhou J, Waskowicz LR, Lim A, Liao XH, Lian B, Masamune H, Refetoff S, Tran B, Koeberl DD, Yen PM. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. Thyroid. 2019 Aug;29(8):1158-1167. doi: 10.1089/thy.2019.0007. PMID: 31337282; PMCID: PMC6707038. 3: Mondal S, Mugesh G. Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and their action. Mol Cell Endocrinol. 2017 Dec 15;458:91-104. doi: 10.1016/j.mce.2017.04.006. Epub 2017 Apr 11. PMID: 28408161. 4: Tancevski I, Eller P, Patsch JR, Ritsch A. The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs. 2009 Sep;10(9):912-8. PMID: 19705333; PMCID: PMC2993058. 5: Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL, Erion MD. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol. 2009 Feb;156(3):454-65. doi: 10.1111/j.1750-3639.2009.00038.x. Epub 2009 Jan 22. PMID: 19183199; PMCID: PMC2697679. 6: Boyer SH, Jiang H, Jacintho JD, Reddy MV, Li H, Li W, Godwin JL, Schulz WG, Cable EE, Hou J, Wu R, Fujitaki JM, Hecker SJ, Erion MD. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem. 2008 Nov 27;51(22):7075-93. doi: 10.1021/jm800824d. PMID: 18975928. 7: Fujitaki JM, Cable EE, Ito BR, Zhang BH, Hou J, Yang C, Bullough DA, Ferrero JL, van Poelje PD, Linemeyer DL, Erion MD. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos. 2008 Nov;36(11):2393-403. doi: 10.1124/dmd.108.021642. Epub 2008 Aug 14. PMID: 18703645.